Research progress on GP73 in malignant tumors

Abstract

Rong Liang, Ziyu Liu, Xuemin Piao, Mingtang Zuo, Jinyan Zhang, Zhihui Liu, Yongqiang Li, Yan Lin Department of Medical Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, People’s Republic of China Abstract: Malignant cancer is one of the most serious diseases that currently endanger human health. As most tumors are diagnosed at an advanced stage, the current treatments show poor therapeutic efficacy, and the patients have poor prognosis. However, a 5-year survival rate higher than 80% could be achieved if tumors are diagnosed at an early stage. Therefore, early diagnosis and treatment play important roles in the prevention and treatment of malignant tumors, and serum tumor markers are important for the early diagnosis of malignant cancers. Recent studies have shown that GP73, a transmembrane protein, has greater diagnostic value in primary liver cancer than in other types of cancers, and research on the regulation of GP73 expression has unveiled broad prospects in anticancer targeted therapy. Thus, GP73, as a new tumor marker, deserves further study. Keywords: GP73, malignant tumors, tumor marker, diagnosis, prognosis

Keywords

• GP73
• malignant tumors
• tumor marker